PT - JOURNAL ARTICLE AU - Yee Hui Yeo AU - Sz-Iuan Shiu AU - Hsiu J Ho AU - Biyao Zou AU - Jaw-Town Lin AU - Ming-Shiang Wu AU - Jyh-Ming Liou AU - Chun-Ying Wu ED - , TI - First-line <em>Helicobacter pylori</em> eradication therapies in countries with high and low clarithromycin resistance: a systematic review and network meta-analysis AID - 10.1136/gutjnl-2016-311868 DP - 2018 Jan 01 TA - Gut PG - 20--27 VI - 67 IP - 1 4099 - http://gut.bmj.com/content/67/1/20.short 4100 - http://gut.bmj.com/content/67/1/20.full SO - Gut2018 Jan 01; 67 AB - Objective To determine the optimal regimen of different first-line Helicobacter pylori eradication therapies according to the clarithromycin resistance rate.Design Electronic search for articles published between January 2005 and April 2016. Randomised, controlled trials that reported the effectiveness of first-line eradication therapies in treatment-naïve adults were included. Two independent reviewers performed articles screening and data extraction. Network and traditional meta-analyses were conducted using the random effect model. Subgroup analyses were performed to determine the ranking of regimens in countries with high (&gt;15%) and low (&lt;15%) clarithromycin resistance. Data including adverse events and therapeutic cure rate were also extracted and analysed.Results 117 trials (totally 32 852 patients) for 17 H. pylori eradication regimens were eligible for inclusion. Compared with 7-day clarithromycin-based triple therapy, sequential therapy (ST) for 14 days had the highest effectiveness (OR=3.74, 95% CrI 2.37 to 5.96). ST-14 (OR=6.53, 95% CrI 3.23 to 13.63) and hybrid therapy (HY) for 10 days or more (OR=2.85, 95% CrI 1.58 to 5.37) represented the most effective regimen in areas with high and low clarithromycin resistance, respectively. The effectiveness of standard triple therapy was below therapeutic eradication rate in most of the countries. Longer duration was associated with higher eradication rate, but with a higher risk of events that lead to discontinuation.Conclusions ST and HY appeared to be the most effective therapies in countries with high and low clarithromycin resistance, respectively. The clinical decision for optimal regimen can be supported by referring to the rank ordering of relative efficacies stratified by local eradication rates, antibiotic resistance and safety profile.Trial registration number CRD42015025445.